FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Csilla Ozvegy-Laczka

Research Profile

Chemicals & Drugs

Anatomy

Physiology

Phenomena

Co-author Network

Publications

TOP 3
Agnes Telbisz; Tamás Hegedűs; András Váradi; Csilla Ozvegy-Laczka; Balázs Sarkadi
Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein.
Csilla Hegedüs; György Kéri; Katalin Német; László Őrfi; Csilla Ozvegy-Laczka; Jeffrey Settleman; Gergely Szakács; Krisztina Truta-Feles; András Váradi; György Várady; Géza Antalffy; Balázs Sarkadi
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Csilla Hegedüs; Ildikó Kasza; Katalin Német; Tamás I Orbán; Géza Antalffy; Anna Brózik; Krisztina Truta-Feles; András Váradi; Csilla Ozvegy-Laczka; Balázs Sarkadi
PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Csilla Ozvegy-Laczka (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Agnes Telbisz; Tamás Hegedűs; András Váradi; Csilla Ozvegy-Laczka; Balázs Sarkadi
Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein.
The Biochemical journal 2013;450(2):387-95.
2012: Csilla Hegedüs; György Kéri; Katalin Német; László Őrfi; Csilla Ozvegy-Laczka; Jeffrey Settleman; Gergely Szakács; Krisztina Truta-Feles; András Váradi; György Várady; Géza Antalffy; Balázs Sarkadi
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Biochemical pharmacology 2012;84(3):260-7.
2012: Csilla Hegedüs; Ildikó Kasza; Katalin Német; Tamás I Orbán; Géza Antalffy; Anna Brózik; Krisztina Truta-Feles; András Váradi; Csilla Ozvegy-Laczka; Balázs Sarkadi
PI3-kinase and mTOR inhibitors differently modulate the function of the ABCG2 multidrug transporter.
Biochemical and biophysical research communications 2012;420(4):869-74.
2009: C Hegedus; Csilla Ozvegy-Laczka; Agota Apáti; Mária Magócsi; Katalin Német; László Õrfi; G Kéri; M Katona; Z Takáts; A Váradi; Gergely Szakács; Balázs Sarkadi
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
British journal of pharmacology 2009;158(4):1153-64.
2009: Orsolya Polgar; Lilangi S Ediriwickrema; Robert W Robey; Ajay Sharma; Ramanujan S Hegde; Yongfu Li; Di Xia; Yvona Ward; Michael Dean; Csilla Ozvegy-Laczka; Balázs Sarkadi; Susan E Bates
Arginine 383 is a crucial residue in ABCG2 biogenesis.
Biochimica et biophysica acta 2009;1788(7):1434-43.
2009: Csilla Hegedus; Csilla Ozvegy-Laczka; Gergely Szakács; Balázs Sarkadi
Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors?
Current cancer drug targets 2009;9(3):252-72.
2008: Csilla Ozvegy-Laczka; Rozália Laczkó; Csilla Hegedus; Thomas Litman; György Várady; Katalin Goda; Tamás Hegedus; Nikolay V Dokholyan; Brian P Sorrentino; András Váradi; Balázs Sarkadi
Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter.
The Journal of biological chemistry 2008;283(38):26059-70.
2008: Gergely Szakács; András Váradi; Csilla Ozvegy-Laczka; Balázs Sarkadi
The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox).
Drug discovery today 2008;13(9-10):379-93.
2008: Tamás I Orbán; László Seres; Csilla Ozvegy-Laczka; N Barry Elkind; Balázs Sarkadi; László Homolya
Combined localization and real-time functional studies using a GFP-tagged ABCG2 multidrug transporter.
Biochemical and biophysical research communications 2008;367(3):667-73.
2007: Agnes Telbisz; Marianna Müller; Csilla Ozvegy-Laczka; László Homolya; Lajos Szente; András Váradi; Balázs Sarkadi
Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter.
Biochimica et biophysica acta 2007;1768(11):2698-713.
2006: Istvan Szatmari; György Vámosi; Peter Brazda; Balint Balint; Szilvia Benko; Lajos Széles; Viktória Jeney; Csilla Ozvegy-Laczka; Attila Szántó; Endre Barta; József Balla; Balázs Sarkadi; Laszlo Nagy
Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells.
The Journal of biological chemistry 2006;281(33):23812-23.
2006: Orsolya Polgar; Csilla Ozvegy-Laczka; Robert W Robey; Kuniaki Morisaki; Masaki Okada; Akina Tamaki; Gabriella Koblos; N Barry Elkind; Yvona Ward; Michael Dean; Balázs Sarkadi; Susan E Bates
Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization.
Biochemistry 2006;45(16):5251-60.
2006: Judit Cervenak; Hajnalka Andrikovics; Csilla Ozvegy-Laczka; Attila Tordai; Katalin Német; András Váradi; Balázs Sarkadi
The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology.
Cancer letters 2006;234(1):62-72.
2005: Kuniaki Morisaki; Robert W Robey; Csilla Ozvegy-Laczka; Yasumasa Honjo; Orsolya Polgar; Kenneth Steadman; Balázs Sarkadi; Susan E Bates
Single nucleotide polymorphisms modify the transporter activity of ABCG2.
Cancer chemotherapy and pharmacology 2005;56(2):161-72.
2005: N Barry Elkind; Zsófia Szentpétery; Agota Apáti; Csilla Ozvegy-Laczka; György Várady; Olga Ujhelly; Katalin Szabó; László Homolya; András Váradi; László Buday; György Kéri; Katalin Német; Balázs Sarkadi
Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
Cancer research 2005;65(5):1770-7.
2005: Csilla Ozvegy-Laczka; György Várady; Gabriella Köblös; Olga Ujhelly; Judit Cervenak; John D Schuetz; Brian P Sorrentino; Gerrit-Jan Koomen; András Váradi; Katalin Német; Balázs Sarkadi
Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.
The Journal of biological chemistry 2005;280(6):4219-27.
2005: Csilla Ozvegy-Laczka; Judit Cserepes; N Barry Elkind; Balázs Sarkadi
Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2005;8(1-2):15-26.
2005: Csilla Ozvegy-Laczka; Gabriella Köblös; Balázs Sarkadi; András Váradi
Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
Biochimica et biophysica acta 2005;1668(1):53-63.
2004: Judit Cserepes; Zsófia Szentpétery; László Seres; Csilla Ozvegy-Laczka; Thomas Langmann; Gerd Schmitz; Hristos Glavinas; Izabella Klein; László Homolya; András Váradi; Balázs Sarkadi; N Barry Elkind
Functional expression and characterization of the human ABCG1 and ABCG4 proteins: indications for heterodimerization.
Biochemical and biophysical research communications 2004;320(3):860-7.
2004: Balázs Sarkadi; Csilla Ozvegy-Laczka; Katalin Német; András Váradi
ABCG2 -- a transporter for all seasons.
FEBS letters 2004;567(1):116-20.
2004: Csilla Ozvegy-Laczka; Tamás Hegedus; György Várady; Olga Ujhelly; John D Schuetz; András Váradi; György Kéri; László Õrfi; Katalin Német; Balázs Sarkadi
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.
Molecular pharmacology 2004;65(6):1485-95.